U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
CAMBRIDGE, Mass., May 08, 2018 -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Evelo has granted the underwriters a 30-day option to purchase up to an additional 796,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. Evelo’s common stock is expected to begin trading on The Nasdaq Global Select Market on May 9, 2018 under the ticker symbol “EVLO.” All of the common stock is being offered by Evelo. The gross proceeds of the offering are expected to be $85 million, excluding any exercise of the underwriters’ option.
Morgan Stanley, Cowen and BMO Capital Markets are acting as book-running managers for the offering. JMP Securities is acting as lead manager for the offering.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at (631) 274-2806; or BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, Attn: Equity Syndicate Department, by telephone at 800-414-3627, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Contact
Evelo Biosciences
Stefan Riley
617-704-2333
[email protected]
